LeMaitre Vascular (NASDAQ: LMAT) stock: the official figures
LeMaitre Vascular (LEMAITRE VASCULAR, INC.) is listed on Nasdaq under the ticker LMAT and belongs to the health care sector. In fiscal 2025 it reported revenue of $249.6m and a net profit of $57.7m, according to the annual accounts it filed with the regulator.
Identifiers for LeMaitre Vascular: SEC CIK 1158895.
Fiscal 2025 figures
| Item | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $249.6m | $219.9m | +13.5% |
| Operating profit | $67.9m | $52.3m | +30.0% |
| Net profit | $57.7m | $44.0m | +31.1% |
| Earnings per share | $2.55 | $1.96 | +30.1% |
| Operating margin | 27.2% | 23.8% | +3.4 pts |
| Net margin | 23.1% | 20.0% | +3.1 pts |
| Total assets | $615.7m | $551.8m | +11.6% |
| Equity | $393.5m | $337.3m | +16.7% |
| Cash | $28.2m | $25.6m | +10.3% |
| Operating cash flow | $81.3m | $44.1m | +84.1% |
Margins are calculated from the filed figures: operating profit and net profit over revenue.
10 fiscal years
| Fiscal year | Revenue | Operating profit | Net profit | Earnings per share | Document |
|---|---|---|---|---|---|
| 2025 | $249.6m | $67.9m | $57.7m | $2.55 | Annual report |
| 2024 | $219.9m | $52.3m | $44.0m | $1.96 | Annual report |
| 2023 | $193.5m | $36.7m | $30.1m | $1.36 | Annual report |
| 2022 | $161.7m | $26.8m | $20.6m | $0.94 | Annual report |
| 2021 | $154.4m | $36.4m | $26.9m | $1.27 | Annual report |
| 2020 | $129.4m | $28.8m | $21.2m | $1.05 | Annual report |
| 2019 | $117.2m | $21.2m | $17.9m | $0.91 | Annual report |
| 2018 | $105.6m | $28.2m | $22.9m | $1.18 | Annual report |
| 2017 | $100.9m | $21.1m | $17.2m | $0.91 | Annual report |
| 2016 | $89.2m | $16.3m | $10.6m | $0.57 | Annual report |
The full income statement, balance sheet and cash flow statement are in the annual accounts of LeMaitre Vascular. Year by year: dividends paid. Purchases and sales by its executives and directors are in insider transactions.
Dividends
In fiscal 2025, LeMaitre Vascular paid $18.1m in dividends, 31.4% of its net profit, according to its cash flow statement.
| Fiscal year | Dividends paid | Share of net profit |
|---|---|---|
| 2025 | $18.1m | 31.4% |
| 2024 | $14.4m | 32.6% |
| 2023 | $12.4m | 41.3% |
| 2022 | $11.0m | 53.2% |
| 2021 | $9.3m | 34.7% |
| 2020 | $7.7m | 36.3% |
| 2019 | $6.7m | 37.6% |
| 2018 | $5.4m | 23.7% |
| 2017 | $4.2m | 24.3% |
| 2016 | $3.3m | 31.4% |
Cash paid out as dividends during the fiscal year, including dividends to minority shareholders of subsidiaries when the company does not report them separately. It is not the dividend per share.
Frequently asked questions about LeMaitre Vascular
- How much did LeMaitre Vascular earn in fiscal 2025?
- LeMaitre Vascular reported a net profit of $57.7m for fiscal 2025, on revenue of $249.6m. The year before it reported a net profit of $44.0m.
- Does LeMaitre Vascular pay a dividend?
- In fiscal 2025, LeMaitre Vascular paid $18.1m in dividends, 31.4% of its net profit, according to its cash flow statement.
- What are the earnings per share of LeMaitre Vascular?
- They were $2.55 in fiscal 2025, compared with $1.96 the year before.
- Where is LeMaitre Vascular listed?
- LeMaitre Vascular is listed on Nasdaq under the ticker LMAT and belongs to the health care sector.
- Where do the figures for LeMaitre Vascular come from?
- From the annual report (Form 10-K) that LeMaitre Vascular files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
The annual accounts come from the annual report (Form 10-K) that LeMaitre Vascular files with the SEC, the US securities regulator. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.
Dividend per share of LeMaitre Vascular by fiscal year, with the filing behind every figure: LeMaitre Vascular dividend history.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.